
Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.
Panelists discuss the common barriers to implementing new chronic kidney disease (CKD) treatments and guidelines in clinical practice, as well as the role of pharmaceutical partners in overcoming these challenges to enhance CKD treatment adoption.






